SureTrader
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

PMCB RSS Feed
Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, bulldurham, TraderpennyX, Peacefulwendy, TheBestInvest, $Pistol Pete$
Search This Board:
Last Post: 7/7/2015 10:13:10 PM - Followers: 543 - Board type: Free - Posts Today: 66

Welcome to PharmaCyte BioTech

PharmaCyte Biotech Corporate Video – June 1, 2015


https://www.youtube.com/watch?v=VBebR1vWt50&feature=youtu.be

$PMCB Analyst Report from Reuters (http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114728570)


FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment

http://www.nuvilex.com/latest-news/149-fda-grants-orphan-drug-designation-to-nuvilex-for-pancreatic-cancer-treatment








Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious:
Data from Two Clinical Trials in Pancreatic Cancer

http://www.mdpi.com/1999-4923/6/3/447




















ThaiTECT ???????? 14 - Drug Development Part I : International Experiences

http://www.youtube.com/watch?v=nL_LznwTdKk


Nuvilex/Austrianova declared the winner of the 2014 Best Innovation Award
 
http://client.irwebkit.com/Nuvilex/news/2433458






Encapsulation of Insulin Producing Cells for Diabetes Treatment Using 
Alginate and Cellulose Sulphate as Bioencapsulation Polymers


http://austrianova.com/wp-content/uploads/2014/09/DRTOA-1-102-final.compressed.pdf


NUVILEX (NVLX)- The Next Great Biotech Story (VIDEO)

                                            

PharmaCyte Company Address
   PharmaCyte BioTech, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851
   email:
 info@pharmacytebiotech.com


Market Value:
$76,201,902 a/o Mar 11, 2015

Shares Outstanding:
699,292.029 a/o Dec 15, 2014

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

Float:
529,206,849 a/o Aug 26, 2014


Short Selling Data

Short Interest: 363,107 (1.685) a/o Feb 13, 2015

For more updated information please visit: 


http://www.otcmarkets.com/stock/PMCB/profile


Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations


Jamien Jones 
Blueprint Life Science Group 
Telephone: 415.375.3340 Ext. 103 
jjones@bplifescience.com 

http://bplifescience.com/clients.html 

                                               

All News Releases: 
http://www.nuvilex.com/latest-news

All Information about Nuvilex:
http://www.stockmarketmediagroup.com/features/nvlx/

What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans.


http://austrianova.com/products/ 



PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.



">

Austria Nova Demonstration Video

 
 

SMMG Radio Interview with COO Dr. Crabtree ~ 2013





Shareholder Update with CEO & COO via SMMG Interview ~ July 2014






The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool


Management Team:

 

Kenneth L. Waggoner, Chief Executive Officer and President:


Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.

 

Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:



Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Walter H. Gunzburg – Chief Scientific Officer:



Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. As well as being a full Professor of Virology at the University of Vienna since 1996, he has had many years of experience in the biotech industry. He was a scientific advisor to the international vaccine company, Bavarian Nordic, from 1994-2001 and was involved in their IPO. He has also been an scientific advisor to the German biotech companies, Paktis and Liponova, as well as the U.S. biotech company, Tocagen Inc., all of which developed/are developing advanced medicinal treatments for cancer. He was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development from 2003-2011. Currently, he is a board member of ViruSure, a virus and prion testing company located in Vienna that he cofounded.

Prof. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy as well as xenotransplantation for many years. He was a member of the German Medical Association's Central Commission for Somatic Gene Therapy. He has also interacted with a number of regulatory agencies including the US FDA, EMA, TGA, HSA and Thai-FDA and was on the review panel for the Paul Ehrlich Institute, Langen, Germany. Prof. Gunzburg continues to be an active researcher and has published more than 130 peer-reviewed publications in international scientific and medical journals such as NatureThe Lancet,Proceedings of the National Academy of Sciences USA and Cancer Research as well as co-authoring the first German language textbook on gene therapy. He is also a member of the editorial board of a number of international cell and gene therapy journals including Trends in Molecular Medicine, and continues to be an active reviewer for many top tier journals as well as grant funding agencies.


Dr. Matthias Lohr as Chairman of Scientific Advisory Board:



Matthias Löhr was appointed professor of gastroenterology & hepatology at Karolinska Institutet in 2007, incoming from the Univ. Heidelberg/dkfz. From the times of his MD thesis through PhD and lateron, he concentrated on several aspects of the pancreas, both in clinical medicine, translational and basic sciences. He is heading the Pancreas Research Team at Gastrocentrum and leading the KICancer Diagnose-related network for HPB tumors. For hte European Gastroenterologists (UEG), he is sitting in several committees at the EU in Brussels. He is also leading the Pancreas 2000 program, an educational program for future pancreatologists in Europe.

Thomas Liquard - Chairman of the Audit Committe


Mr. Liquard is a seasoned pharmaceutical industry executive whose past experiences include serving as Chief Executive of Alchemia Limited and as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio for Pfizer in New York.

 

Dr. Eva Maria (Lilli) Brandtner – Director of Diabetes Program Development




 

Following receipt of her Doctorate in Natural Sciences in the areas of Biochemical Microbiology and Molecular Genetics in 2001, Dr. Brandtner served as a Postdoctoral Scientist and Senior Postdoctoral Fellow at Austrianova Biomanufacturing AG in Austria where she was involved in the development of retroviral vectors for gene therapy.  In 2007, Dr. Brandtner moved to Singapore and became Project Manager for work on the cell-based therapy of liver cancer at the same company.  Shortly thereafter, Dr. Brandtner was promoted to Senior Scientist at Austrianova Pte Ltd (Austrianova) where she oversaw the development of numerous projects concerned with live cell Bioencapsulation.  This was followed in 2010 by her promotion to Chief Scientist at Austrianova, responsible for all encapsulation projects in medicine and biology.  Most importantly, while at Austrianova, Dr. Brandtner was intimately involved in all of the preclinical work done there that included the use of live cell encapsulation in developing a treatment for insulin-dependent diabetes.  Due to family commitments, in 2012 Dr. Brandtner left Singapore to return to Austria where she is currently employed as Head of the Bioencapsulation Unit at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT).

Dr. Brandtner is co-inventor on two granted patents and is named on several additional patents that are in preparation.  She has co-authored numerous research reports that have been published in reputable scientific journals and has presented research results at national and international scientific conferences and meetings.  Dr. Brandtner is a member of the European Association for the Study of Diabetes (EASD), the Austrian Diabetes Association (ÖDG) and the European Society for Gene and Cell Therapy (ESGCT).



 

 






Stock Chart http://www.otcmarkets.com/stock/NVLX/chart
Company Info http://www.otcmarkets.com/stock/NVLX/company-info
Recent News http://www.otcmarkets.com/stock/NVLX/news
Financials http://www.otcmarkets.com/stock/NVLX/financials
Filings and Disclosure http://www.otcmarkets.com/stock/NVLX/filings
Short Sales http://www.otcmarkets.com/stock/NVLX/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/NVLX/insider-transactions
Research Reports http://www.otcmarkets.com/stock/NVLX/research
Summary http://finance.yahoo.com/q?s=NVLX
Historical Prices http://finance.yahoo.com/q/hp?s=NVLX+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=NVLX
Basic Chart http://finance.yahoo.com/q/bc?s=NVLX+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=NVLX+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=NVLX+Headlines
Press Releases http://finance.yahoo.com/q/p?s=NVLX+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=NVLX+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=NVLX+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=NVLX+Industry
Major Holders http://finance.yahoo.com/q/mh?s=NVLX+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=NVLX+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=NVLX+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=NVLX
Balance Sheet http://finance.yahoo.com/q/bs?s=NVLX
Cash Flow http://finance.yahoo.com/q/cf?s=NVLX+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/NVLX
Market Watch http://www.marketwatch.com/investing/stock/NVLX
Bloomberg http://www.bloomberg.com/quote/NVLX:US
Morningstar http://quotes.morningstar.com/stock/s?t=NVLX
Bussinessweek http://investing.businessweek.com/research/st...icker=NVLX
Barchart http://www.barchart.com/quotes/stocks/NVLX
OTC Short Report http://otcshortreport.com/index.php?index=NVLX
Investopedia http://www.investopedia.com/markets/stocks/NVLX/?wa=0

Features http://www.stockmarketmediagroup.com/features/nvlx/

 

                                  

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PMCB
Current Price
Volume:
Bid Ask Day's Range
Wiki
PMCB News: PharmaCyte Biotech Releases HealthWatch Segment Featured on Discovery Channel 06/30/2015 08:30:00 AM
PMCB News: PharmaCyte Biotech’s Cancer and Diabetes Treatments Airing Nationwide on Discovery Channel 06/29/2015 08:30:00 AM
PMCB News: PharmaCyte Biotech Enters Into Research and Consulting Agreements With University of Technology Sydney 06/23/2015 09:25:00 AM
PMCB News: PharmaCyte Biotech Showcasing Technology and Treatments at 2015 BIO International Convention 06/16/2015 09:25:00 AM
PMCB News: PharmaCyte Biotech Advances Cannabinoid Research With Schedule 1 License 06/15/2015 09:25:00 AM
PostSubject
#37735  Sticky Note WOW... All that in under 4 minutes on Discovery Channel... bulldurham 06/30/15 09:10:50 AM
#37576  Sticky Note $PMCB Breaking News PharmaCyte Biotech’s Cancer a $Pistol Pete$ 06/29/15 09:08:57 AM
#36793  Sticky Note $PMCB Treatment Being Studied Involves a Combo of $Pistol Pete$ 06/17/15 03:58:32 PM
#36202  Sticky Note $PMCB PharmaCyte Biotech Corporate Video – June 1, 2015[ $Pistol Pete$ 06/01/15 07:31:26 PM
#36172  Sticky Note $PMCB On May 28, 2015, Stonegate Capital Partners $Pistol Pete$ 06/01/15 02:25:12 AM
#31423  Sticky Note PharmaCyte Biotech Initiates First Preclinical Study of Its TheBestInvest 02/04/15 11:38:18 AM
#18112  Sticky Note EVERYONE please keep your posts on-topic. The topic IH Geek [Dave] 03/14/14 12:28:20 PM
#38164   Posted while back Old Science.. I, have talked lastcall59 07/07/15 10:13:10 PM
#38162   love your dd frosr spot on about PMCB thenewmixer 07/07/15 07:22:36 PM
#38161   Everyone following cell research 10-15 years ago knew frosr6 07/07/15 05:53:54 PM
#38160   Why would anybody buy PMCB now or at frosr6 07/07/15 04:54:41 PM
#38159   I agree bio. Unfortunately, there are very Peacefulwendy 07/07/15 04:52:44 PM
#38158   Austrianova did. Didn't help them. frosr6 07/07/15 04:47:15 PM
#38157   Exactly!!! Unless of coarse pmcb is one of frosr6 07/07/15 04:46:15 PM
#38156   CHART LOOKS TERRIBLE HERE Alydyr 07/07/15 04:41:04 PM
#38155   any you feel good about that? if you thenewmixer 07/07/15 04:39:53 PM
#38154   is the fact that KW has watched PMCB thenewmixer 07/07/15 04:35:19 PM
#38153   That's right Wendy. So many made up BioNewton 07/07/15 04:27:18 PM
#38152   what do you think PMCB pr tomorrow....how you thenewmixer 07/07/15 04:18:04 PM
#38151   Thank you for proving my point....this Dr sat thenewmixer 07/07/15 04:14:22 PM
#38150   what was PMCBs pps before the smmg thenewmixer 07/07/15 04:07:25 PM
#38149   The article was published 10 years ago. Peacefulwendy 07/07/15 04:05:42 PM
#38148   COMPLETE TUMOR REMISSION, to bad they are no thenewmixer 07/07/15 04:01:50 PM
#38147   .15 COMING SOON - VERY GOOD BioNewton 07/07/15 03:59:24 PM
#38146   I love saying COMPLETE TUMOR REMISSION. I BioNewton 07/07/15 03:57:32 PM
#38144   .07 HERE SOON - NOT GOOD Alydyr 07/07/15 02:21:35 PM
#38143   $PMCB on Discovery Channel $Pistol Pete$ 07/07/15 02:18:00 PM
#38142   "Complete Tumor Remission say that a few times thenewmixer 07/07/15 02:15:19 PM
#38141   $PMCB Corporate Video A MUST WATCH $Pistol Pete$ 07/07/15 02:13:14 PM
#38140   what kind of a doctor would sit on thenewmixer 07/07/15 02:08:37 PM
#38139   HARD TO ROOT AGAINST THOSE WITH CANCER - BioNewton 07/07/15 01:50:48 PM
#38138   WHAT A DISASTER HERE Alydyr 07/07/15 01:45:45 PM
#38137   PharmaCyte Biotech's Cancer Treatment Shows "Complete Tumor Remission" BioNewton 07/07/15 01:45:15 PM
#38136   $PMCB will be fine. $Pistol Pete$ 07/07/15 01:45:11 PM
#38135   PMCB is better than a sub-penny stock at BioNewton 07/07/15 01:40:06 PM
#38134   PMCB better ok its not a 9cents stock thenewmixer 07/07/15 01:36:10 PM
#38133   Actually its better than earlier. We were BioNewton 07/07/15 01:24:01 PM
#38131   JUST KEEPS GETTING WORSE HERE Alydyr 07/07/15 01:05:04 PM
#38130   Agreed Go $PMCB $Pistol Pete$ 07/07/15 12:23:39 PM
#38129   For those that think .10 seems cheap the A_realist 07/07/15 12:23:39 PM
#38128   Pistol, if it goes below $0.10 I will pennyvestor 07/07/15 12:15:59 PM
#38127   Hotelier51, just a reminder that he did not pennyvestor 07/07/15 12:14:29 PM
#38126   Just a reminder CEO Ken Waggoner's Last Company.... Hotelier51 07/07/15 12:11:22 PM
#38125   Congrats Bud. I am loading big on $.10 $Pistol Pete$ 07/07/15 12:10:06 PM
#38124   Pete, I bought 4,000 more shares today as pennyvestor 07/07/15 12:08:16 PM
#38123   Time for me to load up $.10 at $Pistol Pete$ 07/07/15 11:58:59 AM
#38122   Just as I predicted, PMCB now below a dime. Alydyr 07/07/15 11:55:23 AM
#38121   rofl...I know. You are correct Sir! :) TheSaint09 07/07/15 11:52:06 AM
#38120   the whole world can't be wrong about PMCB thenewmixer 07/07/15 11:48:57 AM
#38118   Yep, time to load up. I love BioNewton 07/07/15 11:43:16 AM
#38117   This is what happens when you have a thenewmixer 07/07/15 11:38:04 AM
#38116   This must be the new cannabis stock scam StockSleuth 07/07/15 11:35:17 AM
#38115   It may go below .10 today. You A_realist 07/07/15 11:32:06 AM
#38114   HMMMMM, I don't think so. Dr. Brandtner BioNewton 07/07/15 11:29:58 AM
#38113   Oops - meant will NOT be happening. BioNewton 07/07/15 11:25:42 AM
#38112   Doesn't look like the buy at .10 sell BioNewton 07/07/15 11:01:26 AM
#38111   PMCB no GMP=nothing thenewmixer 07/07/15 10:39:22 AM
PostSubject